Check Before You Invest : Haleos Labs Ltd

Q: Which industry/sub-sector does Haleos Labs Ltd belong to?

Haleos Labs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q: Is Haleos Labs Ltd a good quality company?

Haleos Labs Ltd is a average quality company, based on a somewhat consistent multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Haleos Labs Ltd undervalued or overvalued?

Haleos Labs Ltd appears Overvalued, as its key valuation ratios are higher than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: 26.83, Historic Median: 16.04. Price to Book, Current: 2.3, Historic Median: 1.50. Price to Sales, Current: 1.51, Historic Median: 0.74. EV to EBITDA, Current: 12.99, Historic Median: 8.56

Q: Is Haleos Labs Ltd a good buy now?

Haleos Labs Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Haleos Labs Ltd?

Haleos Labs Ltd revenue growth is 11.1% for FY-2025, which is above its 5-year CAGR of 5.35%, indicating faster growth.

Q: Gross Profit margin of Haleos Labs Ltd?

Haleos Labs Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.9% for FY-2025, which is above its 5-year median of 8.9%, indicating increasing margins.

Q: Operating Profit Margin of Haleos Labs Ltd?

Haleos Labs Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 13.29% for FY-2025, which is above its 5-year median of 11.45% indicating increasing margins.

Q: Net Profit Margin of Haleos Labs Ltd?

Haleos Labs Ltd Net Profit Margin is 6.41% for FY-2025, is above its 5-year median of 5.06%, indicating increasing margins. Profitability Metrics. Gross Profit Margin (%), Current: 10.9, Historic Median: 8.9. Operating Profit Margin (%), Current: 13.29, Historic Median: 11.45. Net Profit Margin (%), Current: 6.41, Historic Median: 5.06

Q: Return on Asset of Haleos Labs Ltd?

Haleos Labs Ltd Return on Asset is 5.95%, which is above its 5-year historical median of 5.19%, indicating improved asset utilization efficiency.

Q: Return on capital employed (ROCE) of Haleos Labs Ltd?

Haleos Labs Ltd Return on capital employed is 14.03% for FY-2025, which is in line with its 5-year historical median of 14.03%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Check Before You Invest : Haleos Labs Ltd

Snapshot

Q.1 Which industry/sub-sector does Haleos Labs Ltd belong to?

Haleos Labs Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Haleos Labs Ltd a good quality company?

Haleos Labs Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Haleos Labs Ltd undervalued or overvalued?

Haleos Labs Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	26.83	16.04
Price to Book	2.3	1.50
Price to Sales	1.51	0.74
EV to EBITDA	12.99	8.56

Q.4 Is Haleos Labs Ltd a good buy now?

Haleos Labs Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Haleos Labs Ltd?

Haleos Labs Ltd revenue growth is 11.1% for FY-2025, which is above its 5-year CAGR of 5.35%, indicating faster growth.

Q.2 Gross Profit margin of Haleos Labs Ltd?

Haleos Labs Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.9% for FY-2025, which is above its 5-year median of 8.9%, indicating increasing margins.

Q.3 Operating Profit Margin of Haleos Labs Ltd?

Haleos Labs Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 13.29% for FY-2025, which is above its 5-year median of 11.45% indicating increasing margins.

Q.4 Net Profit Margin of Haleos Labs Ltd?

Haleos Labs Ltd Net Profit Margin is 6.41% for FY-2025, is above its 5-year median of 5.06%, indicating increasing margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	10.9	8.9
Operating Profit Margin (%)	13.29	11.45
Net Profit Margin (%)	6.41	5.06

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Haleos Labs Ltd?

Haleos Labs Ltd Return on Asset is 5.95%, which is above its 5-year historical median of 5.19%, indicating improved asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Haleos Labs Ltd?

Haleos Labs Ltd Return on capital employed is 14.03% for FY-2025, which is in line with its 5-year historical median of 14.03%. The current ROCE is above its estimated weighted average cost of capital (WACC) of 14%, indicating value creation.

Q.7 Return on Equity (ROE) of Haleos Labs Ltd?

Haleos Labs Ltd Return on equity is 11.45% for FY-2025, which is in line with its 5-year historical median of 10.99%, indicating the business is making similar use of its shareholders capital.

Q.8 Cash conversion cycle of Haleos Labs Ltd?

Haleos Labs Ltd Cash conversion cycle is 63 days, above its 5-year historical median of 46 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	1.02	1.07
ROE (%)	11.45	10.99
ROCE (%)	14.03	14.03
Cash Conversion Cycle	63 days	46 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Haleos Labs Ltd?

Haleos Labs Ltd Debt-to-Equity ratio is 0.40, which is above the industry average of 0.14, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Haleos Labs Ltd?

Haleos Labs Ltd Debt to cash flow from operations is 2.82, which is at a moderate level.

Ownership & governance

D: Promoter shareholding and pledge status of Haleos Labs Ltd?

Q.1 Promoter shareholding and pledge status of Haleos Labs Ltd?

Promoters hold 72.11% of the Haleos Labs Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Haleos Labs Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Haleos Labs Ltd vs industry peers?

Haleos Labs Ltd revenue CAGR is 5.35%, compared to the industry median CAGR of 5.52%, indicating stable growth and maintaining its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	11.1	5.5
Gross Profit Growth (%)	37.9	13.9
Operating Profit Growth (%)	25.7	11.6
Net Profit Growth (%)	61.5	12.1

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	1.02	0.79
ROE (%)	11.45	9.17
ROCE (%)	14.03	11.52
Cash Conversion Cycle (days)	62.51	76

Valuation & price assessment

Q.1 Stock return of Haleos Labs Ltd over the last decade?

Over the last 5 year(s), the stock has delivered a CAGR of 22.34% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	-	22.3%	39.2%	28.7%

Q.2 Valuation ratios of Haleos Labs Ltd vs historical?

The current P/E ratio of 26.83 is higher than its historical median of 16.04, indicating that the stock is trading above its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	26.83	16.04	31.09
Price to Book	2.3	1.50	2.85
Price to Sales	1.51	0.74	2.82
EV to EBITDA	12.99	8.56	15.99

Check more companies

5. Wockhardt

8. Neuland Laboratories

9. Acutaas Chemicals

10. Pfizer

Check trending companies

1. Nava Ltd.

2. Honeywell Automation India Ltd.

3. Hindustan Copper Ltd.

4. SBI Life Insurance Company Ltd.

5. Canara Bank

Check Before You Invest : Haleos Labs Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.